팝업레이어 알림

Innovative Gene therapy
for Neurological Diseases
Novel Insights into MicroRNAs
and Senescence
Deciphering Aging & beyond Longevity

스크롤

About ANLBIO

  • We CRAVE longevity with dignity
  • We DECODE nature’s secrets of aging
  • We BLOSSOM technologies
  • MISSION

    In Search of Beauties of Aging & Longevity

  • VISION

    Global top-tier biotech in AAV Gene Therapy & Viral Vector Delivery Platform

  • BUSINESS

    • Gene therapy

      for neurodegenerative CNS disease & rare disease

    • AAV vector platform

      for more effective delivery of therapeutic genes with ease

  • History

    • 2012 ~ 2019

    • 2020 ~ Current

    2019

    Corporate foundation -

    • DEC 2019 Angel capital raised
    • JUL 2019 ANL-101 transfer completed
    • APR 2019 Established

    2017

    Animal model studies & patents -

    • DEC 2017 ANL-101 registered in Korea
    • DEC 2017 ANL-105 filed
    • SEP 2017 ANL-104 filed

    2015

    ANL-101 (AD agent) patent filed -

    • JUN 2015 Filed in Republic of Korea
    • JUN 2016 Filed in US and CHINA (including PCT)

    2012

    Underlying technology - Mainly studied by Dr.Keetae Kim, the co-founder

    • Joint research by IBS(Institue for Basic Science, www.ibs.re.kr) and DGIST(www.dgist.ac.kr)
    • Originally studied the relationship between aging and MicroRNA
    • Found, in hippocampal neurons of mouse, aging-related miRNAs

    2020

    GLP preclinical study & Series A fundraising -

    • DEC 2020 Designated as a preclinical dementia study by a governmental agency of dementia R&D
    • OCT 2020 Experimental medicine produced by OXGENE
    • JUL 2020 ANL-101 patent registered in the US
    • JUN 2020 ANL-104/105 transfer

    Founders / Management

    • Ms.Minjeong KYE

      • Center for Molecular Medicine, University Hospital Cologne, Germany
      • Institute of Human Genetics, Univ. of Cologne, Germany
      • Research fellow, The F.M. Kirby Neurobiology Center, Harvard Medical School
      • PostDoc, Neuroscience, UC, Santa Barbara
      • Ph.D, Max Planck Institute for Experimental Medicine, Univ. of Gottingen, Germany
    • Mr.Myung-yiel LIM

      CFO
      • Strategy Division, BINEX Co., Ltd.
      • Finance & Strategy, Daewoong Pharmaceutical Co., Ltd.
      • M&A Team Head, Eland Group
      • BA in management & economics, Yonsei University
    • Dr.Keetae KIM

      CEO/CSO
      • Principal Investigator, DGIST, Korea
      • Instructor, Virginia Commonwealth Univ.
      • Senior Scientist, Rexahn Pharm. Rockville, MD, US
      • Senior Scientist, LG Biomedical Institute, San Diego, CA, US
      • Research Fellow, Harvard Medical School
      • PhD, Univ. of Texas at Austin
      • MS and BS, Seoul National Univ.
    • Mr.Hongsung MOON

      CEO/COO
      • Chairman, RF Window Co., Ltd.
      • Chairman, ChemOn Inc.
      • President, KD Investment
      • BA in accounting, Dong-Ah Univ.

    Gene Therapy of ANLBIO

    Gene therapy for neurodegenerative diseases targeting microRNA and others

    • DNA Sequence

    • AAV vector
      as a delivering vehicle

    • Single injection

    • Long-lasting effect

    AAV Delivery Platform of ANLBIO

    Safe arrival of transgenes into nuclei is all about gene therapy drugs
    ANLBIO answers to commercial challenges of gene therapy modalities with an innovative delivery platform of viral vectors including AAV

    • Enhanced Random
      Mutagenesis System (ERMS)

    • Mutation of capsid protein
      at multiple position

    • Revamped screening
      by barcode & deep
      sequencing

    • Capsid protein
      library

    PIPELINE

    • miR

    • New AVV

    • Orphan

    miR- based Gene Therapy

    • ANL-101 Alzheimer's Disease
      Efficacy - preclinical
    • ANL-102 MCI
      Efficacy - preclinical
    • ANL-103 Parkinson's Disease
      Efficacy - preclinical
    • ANL-104 Obesity / Diabetes
      In vivo - preclinical
    • ANL-105 Epilepsy
      In vivo - preclinical
    • ANL-106 Eye - Undisclosed
      lead

    New AAV delivery system

    • ANL-201 Virus Vector
      Efficacy - preclinical

    Orphan

    • ANL-301 Undisclosed
      lead
    • ANL-302 Undisclosed
      lead

    Intellectual Property

    • ANL-101

      AD/PD/MCI therapeutic agent

      Registerd
      KOREA (December, 2017), USA (July, 2020)
      Filed
      CHINA, PCT(Jun, 2016 )
    • ANL-104

      Agent for Degenerative Obesity & Diabetes

      Registerd
      In Korea(January, 2021)
      Filed
      In Korea(September, 2017)
    • ANL-105

      Agent for Epilepsy

      Registerd
      In Korea (April, 2021)
      Filed
      In Korea (December, 2017)

    Contact

    Thank you for visiting us
    We are always open to inquires from every potential stakeholders
    Please leave your message to find our idea

    Location

    • Head office

    • SUWON R&D center

    • DAEGU R&D center

    ADDRESS

    #901, Ace Gwang-gyo Tower3, Changryong-daero 256beon-gil, 77, Youngtong-gu, Suwon, Republic of Korea 16229

    View
    ADDRESS

    #708, Ace Gwang-gyo Tower3, Changryong-daero 256beon-gil, 77, Youngtong-gu, Suwon, Republic of Korea 16229

    View
    ADDRESS

    #205, Daegu Techbiz Center, Technogongwon-ro 16, Hyunpung-eup, Dalsung-goon, Daegu, Republic of Korea 43017

    View